Helius Medical Technologies, Inc. to Present at the Investor Summit Group’s Q1 Virtual Summit on March 23rd

Rhea-AI Summary

Helius Medical Technologies (Nasdaq:HSDT) announced its participation in the Investor Summit Group’s Q1 Virtual Summit from March 23-25, 2021. Management will present on March 23 at 2:00 p.m. Eastern Time. A live audio webcast will be available for registered participants. Helius focuses on neurological wellness, aiming to develop non-invasive technologies that enhance the brain's healing capabilities. Its first product, the Portable Neuromodulation Stimulator (PoNS™), is authorized in Canada for treating gait deficits due to multiple sclerosis and chronic balance deficits due to mild traumatic brain injury.

NEWTOWN, Pa., March 17, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the Investor Summit Group’s Q1 Virtual Summit, which is being held from March 23th-25th. Management will present on Tuesday, March 23th at 2:00 p.m. Eastern Time.

A live audio webcast of the conference presentation will be available on the Noble conference website following free registration: https://www.nobleconference.com/register/investor-guest. An archive of the webcast will be available following the conference under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS^TM). For more information, visit www.heliusmedical.com.

About the PoNS™ Device and PoNS Treatment™

The Portable Neuromodulation Stimulator (PoNS™) is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from multiple sclerosis (MS), and chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS™ is an investigational medical device in the United States, the European Union (“EU”), and Australia (“AUS”). The device is currently under review for clearance by the FDA. It is also under premarket review by the AUS Therapeutic Goods Administration. PoNS™ is currently not commercially available in the United States, the European Union or Australia.

Investor Relations Contact:

Westwicke on behalf of Helius Medical Technologies, Inc.
Jack Powell, Vice President
investorrelations@heliusmedical.com

FAQ

When is Helius Medical Technologies presenting at the Investor Summit?

Helius Medical Technologies will present on March 23, 2021, at 2:00 p.m. Eastern Time.

How can I access the webcast for HSDT's presentation?

You can access the live audio webcast by registering on the Noble conference website.

What is the Portable Neuromodulation Stimulator (PoNS™)?

PoNS™ is a non-invasive medical device authorized in Canada for treating gait deficits due to multiple sclerosis and balance deficits from mild traumatic brain injury.

Is the PoNS™ device available in the United States?

Currently, PoNS™ is not commercially available in the United States and is under FDA review.

What upcoming event is HSDT participating in?

Helius Medical Technologies is participating in the Q1 Virtual Summit from March 23-25, 2021.